Search

Your search keyword '"Santini, Stefano Angelo"' showing total 149 results
Start Over Author "Santini, Stefano Angelo"
149 results on '"Santini, Stefano Angelo"'

1. COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity

Author

Gragnani, Laura, Visentini, Marcella, Lorini, Serena, Santini, Stefano Angelo, Lauletta, Gianfranco, Mazzaro, Cesare, Urraro, Teresa, Quartuccio, Luca, Cacciapaglia, Fabio, Ruscitti, Piero, Tavoni, Antonio, Marri, Silvia, Cusano, Giuseppina, Petraccia, Luisa, Naclerio, Caterina, Treppo, Elena, del Frate, Giulia, Di Cola, Ilenia, Raimondo, Vincenzo, Scorpiniti, Daniela, Monti, Monica, Puccetti, Lorenzo, Elia, Giusy, Fallahi, Poupak, Basili, Stefania, Scarpato, Salvatore, Iannone, Florenzo, Casato, Milvia, Antonelli, Alessandro, Zignego, Anna Linda, and Ferri, Clodoveo

Published
2023
Full Text
View/download PDF

2. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Author

Ferri, Clodoveo, Raimondo, Vincenzo, Giuggioli, Dilia, Gragnani, Laura, Lorini, Serena, Dagna, Lorenzo, Bosello, Silvia Laura, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Cuomo, Giovanna, Tavoni, Antonio, De Angelis, Rossella, Cacciapaglia, Fabio, Zanatta, Elisabetta, Cozzi, Franco, Murdaca, Giuseppe, Cavazzana, Ilaria, Romeo, Nicoletta, Codullo, Veronica, Pellegrini, Roberta, Varcasia, Giuseppe, De Santis, Maria, Selmi, Carlo, Abignano, Giuseppina, Caminiti, Maurizio, L'Andolina, Massimo, Olivo, Domenico, Lubrano, Ennio, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Ruscitti, Piero, Urraro, Teresa, Visentini, Marcella, Bellando-Randone, Silvia, Visalli, Elisa, Testa, Davide, Sciascia, Gabriella, Masini, Francesco, Pellegrino, Greta, Saccon, Francesca, Balestri, Eugenia, Elia, Giusy, Ferrari, Silvia Martina, Tonutti, Antonio, Dall’Ara, Francesca, Pagano Mariano, Giuseppa, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Dal Bosco, Ylenia, Foti, Roberta, Di Cola, Ilenia, Scorpiniti, Daniela, Fusaro, Enrico, Ferrari, Tommaso, Gigliotti, Pietro, Campochiaro, Corrado, Francioso, Francesca, Iandoli, Carlo, Caira, Virginia, Zignego, Anna Linda, D'Angelo, Salvatore, Franceschini, Franco, Matucci-Cerinic, Marco, Giacomelli, Roberto, Doria, Andrea, Santini, Stefano Angelo, Fallahi, Poupak, Iannone, Florenzo, and Antonelli, Alessandro

Published
2023
Full Text
View/download PDF

5. Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study

Author

La Gualana, Francesca, primary, Maiorca, Francesca, additional, Marrapodi, Ramona, additional, Villani, Francesca, additional, Miglionico, Marzia, additional, Santini, Stefano Angelo, additional, Pulcinelli, Fabio, additional, Gragnani, Laura, additional, Piconese, Silvia, additional, Fiorilli, Massimo, additional, Basili, Stefania, additional, Casato, Milvia, additional, Stefanini, Lucia, additional, and Visentini, Marcella, additional

Published
2023
Full Text
View/download PDF

6. How future surgery will benefit from SARS-COV-2-related measures: a SPIGC survey conveying the perspective of Italian surgeons

Author

Siragusa, L., Angelico, R., Angrisani, M., Zampogna, B., Materazzo, M., Sorge, R., Giordano, Lucia, Meniconi, R., Coppola, A., Marino, A., Giraudo, G., Esposito, S., Urbani, A., De Pastena, M., Mastrapasqua, R., Garancini, M., Frontal, A., Pascal, G., Martellucc, J., Falb, F., Boscarelli, A., Bertoglio, P., Trecca, E., Galassi, L., Vento, V., Chiappini, A., Antonelli, A., Bennardo, F., Familiari, F., Giannaccare, G., Zappia, A. S., Giuliani, G., Falcone, F., Sebastiani, S., Montuori, M., Rossi, S., Sagnotta, A., Giuliani, B., Imbriani, G. C., Restaino, S., Andreani, L., Di Maria, F., Lagana, A. S., Vitiello, L., Berton, F., Virgilio, E., Palisi, M., Portigliotti, L., Calussi, M., Conti, L., Mauriello, C., Barone, Alessia Maria Addolorata, Saladino, E., Giaquinta, A., Zerb, D., Frazzetta, G., Merola, G., Chierici, A., Bini, R., Centonze, L., De Carlis, R., Ferrario, L., Giani, A., Lauterio, A., Tamini, N., Corti, Serafino, Botteri, E., Andreuccetti, J., D'Alessio, R., Cestaro, G., Clarizia, G., Spolini, A., Carboni, A. S., Benzoni, E., Galiffa, G., Perotti, B., Veroux, M., Randazzo, V., Topa, D., Pranteda, C., Contini, G., Iacusso, C., Voglino, V., Vita, P., Carrano, F. M., Ambrosio, L., Cammarata, R., Capolupo, G. T., Caputo, D., Carannante, F., Cascone, C., Esperto, F., Farolfi, T., Frasca, L., Gallo, I. F., Gibin, G., Giurazza, G., Improta, L., La Vaccara, V., Luffarelli, P., Luvero, D., Marangi, Giuseppe, Masciana, G., Mazzola, A., Mazzotta, E., Miligi, C. I., Montelione, N., Nenna, A., Orsaria, P., Papalia, R., Papalia, G. F., Parisi, F. R., Prata, F., Salzillo, R., Santini, Stefano Angelo, Sofo, F., Zampoli, A., Tanda, C., Altieri, G., Ardito, Francesco, Belia, Francesco, Bianchi, V., Biondi, Alberto, Brisinda, Giuseppe, Chiappetta, M., Ciolli, G., Ciolli, Alessandro, Ferracci, Federica, Ferri, L., Fico, V., Fiorillo, Claudio, Fransvea, Pietro, Galiandro, F., Giovinazzo, F., La Greca, Antonio, Litta, Francesco, Mele, C., Pafundi, D. P., Panettieri, Elena, Papa, Valerio, Patini, Romeo, Perrotta, Generoso, Puccioni, Caterina, Santocchi, P., Armatura, G., Olmi, S., Casoni Pattacini, G., Salgarello, S., Trompetto, M., Bombardini, C., La Rocca, R., Celentano, G., Micalef, A., Mazzella, A., Settembrini, A., Zoia, C., Degrate, L., Musumeci, Giampaolo, Palopoli, C. A. M., Montori, G., Bonati, E., Dinuzzi, V. P., Velluti, F., Balla, A., Bonasia, D. E., Coletta, D., Berardi, Giulia, Colasanti, M., Ferretti, Serena, Gasparoli, C., Mariano, Giuseppantonio, Avenia, S., Cianci, P., Cestino, L., Festa, F., Fazio, F., Ascari, F., Desio, M., Arroyo Murillo, G. A., Cereda, M., Galleano, R., David, G., Pansini, A., Gazia, C., Atzori, G., Desideri, L. F., Famularo, S., Galvanin, J., Giudici, V. M., Mangiameli, Gaetano, Mei, S., Milana, F., Pansa, A., Sacchi, Dario Marco, Testori, A., Di Carlo, Giampiero, Paratore, Mattia, Perrone, U., Vagge, A., Vigano, J., Torre, B., Scotti, M. A., Carbone, G., Cerchione, R., De Nardi, P., Gozzini, L., Ottaviani, Letizia, Senni, C., Piccin, O., Pio, L., Colombo, F., Avantifiori, R., Baldassarri, V., Caronna, R., Cicerchia, P. M., Corallino, D., Crocetti, D., Gallo, Giuseppe, Giovanardi, F., Giovannetti, F., Hassan, R., Iossa, A., Lai, Q., Lancellotti, F., Lucarini, A., Lucchese, S., Mazzarella, Giulio, Melandro, F., Minervini, A., Muttillo, E. M., Palmieri, L., Pasqua, R., Rosiello, F., Salina, Giulia, Sibio, S., Sirignano, P., Tarallo, M., Usai, S., Vanni, C., Viglietta, E., Zambon, M., Conversano, N. I., Epifani, A. G., Milano, Valentina, Sacco, L., Nava, Bruna Maria, Maffioli, A., Giuratrabocchetta, S., Baracchi, F., Zuolo, M., Ceresoli, M., Verdi, D., Belli, Andrea, Pata, F., Piovano, E., Pastore, G., Bernabei, F., Deiana, S., Arceri, A., D'Agostino, Cinzia, Marafante, C., Moggia, E., Parini, S., Moretti, M., Uggeri, F., Pontarolo, N., Fontana, T., Palmisano, Gerardo, Giuffrida, M., Guaitoli, E., Ferretti, C., Iacopino, G., Gioco, R., Roscitano, G., Montanelli, P., Chiappetta, M. F., Pinotti, E., Monati, E., Fazio, G., Di Pietro, F., Damarco, F., Barberis, A., Razzore, A., Pascale, A., Loi, S., Ferrara, F., Rossi, Marco, Lisi, G., Viel, G., Sasia, D., Bono, D., Cordaro, E. R., Giacomelli, E., Giani, I., Seriau, L., Pellino, Giuseppe, Sparavigna, M., Trigiante, G., D'Ambrogio, R. G., Cardella, F., Guzzetti, S., Luzzi, A. -P., Carganico, G., Drago, B., Micheletto, G., Orlandi, R., Cutolo, C., Gibello, U., Mistrangelo, M., Forcignano, E., D'Ugo, S., Losurdo, P., Manitto, M., Caroli, G., Franco, Manuela, Tilocca, P. L., Mendogni, P., Sena, G., Sambucci, D., Luciani, C., Atelli, P., Guida, Maria Antonietta, Marino, Filippo, Morini, A., Sibilla, M. G., Longo, Fabio, Giaccari, S., Vigorita, V., Balduzzi, A., Barra, F., Delogu, D., Milone, E., Bencini, L., Aprile, V., Papini, P., Montemurro, N., Cavallo, Michele, Picciariello, A., Tomasicchio, G., Fittipaldi, A., Maruccia, M., Gerardi, S., Cillara, N., Deidda, Silvia, Demarinis, G., Peiretti, E., Tatti, F., Iovino, C., Isola, G., Progno, V. C., Migliore, M., Badessi, G., Barilla, C., Calleri, G. S., Cianci, Stefano, Fama, F., Fleres, F., Mazzeo, C., Visaloco, M. G., Marchetto, C., Bolognesi, F., Benuzzi, L., Bracchetti, G., Brucchi, F., Manzo, C. A., Scaravilli, L., Ferrari, C., Rocca, A., Napolitano, Paola, Anoldo, P., Caricato, Chiara, Manigrasso, M., Milone, Maria, Napolitano, L., Palomba, G., Schiavone, V., Vetrella, M., Grossi, U., Moletta, L., Annicchiarico, A., Vella, I., Talesa, G., Boggi, U., Aiello, F., Anselmo, Anna, Bacchiocchi, G., Beati, F., Bellato, V., Billeci, F., Blasi, F., Buonomo, O. C., Campanelli, M., Coco, G., Contadini, A., Conte, L. E., D'Ippolito, G., Di Marcantonio, A., Spicchiale, C. F., Afflitto, G. G., Gismondi, A., Gorgolini, G., Granai, A. V., Grande, S., Gravina, A., Guida, A. M., Ingallinella, S., Keci, L., Latini, E., Marino, D., Oddi, F. M., Orecchia, L., Don, C. B. P., Pellicciaro, M., Petagna, L., Pirozzi, B. M., Quaranta, Caterina, Rho, M., Rosina, Alessandro, Santicchia, M. S., Saraceno, F., Schiavone, A., Sensi, B., Spina, A., Sullo, L., Tacconi, F., Taje, R., Vanni, G., Vinci, D., Vita, G., Alba, G., Badalucco, S., Carbone, Luigi, Samorani, O. C., Chisci, G., Cuomo, Rosa, Francia, A., Fusario, D., Gargiulo, B., Pasqui, E., Pasquetti, L., Puoti, P., Resca, L., Cumbo, J., Ganio, S., Vizzielli, Giuseppe, Anastasi, M., Guerra, D., Romanzi, A., Vannelli, A., Baia, M., Giordano L., Barone M., Corti S., Marangi G. (ORCID:0000-0002-6898-8882), Santini S. (ORCID:0000-0003-1956-5899), Ardito F. (ORCID:0000-0003-1596-2862), Belia F., Biondi A. (ORCID:0000-0002-2470-7858), Brisinda G. (ORCID:0000-0001-8820-9471), Ciolli A., Ferracci F., Fiorillo C. (ORCID:0000-0001-7681-3567), Fransvea P. (ORCID:0000-0003-4969-3373), La Greca A. (ORCID:0000-0002-7587-7427), Litta F., Panettieri E., Papa V. (ORCID:0000-0002-3709-8924), Patini R. (ORCID:0000-0001-7358-8763), Perrotta G., Puccioni C., Musumeci G., Berardi G., Ferretti S., Mariano G., Mangiameli G., Sacchi M. (ORCID:0000-0003-2826-8431), Di Carlo G., Paratore M., Ottaviani L. (ORCID:0009-0001-0967-8809), Gallo G., Mazzarella G., Salina G., Milano V., Nava M., Belli A., D'Agostino C., Palmisano G., Rossi M. (ORCID:0000-0002-4539-5670), Pellino G., Franco M., Guida A., Marino F., Longo F., Cavallo M., Deidda S., Cianci S., Napolitano P., Caricato C., Milone M., Anselmo A., Quaranta C., Rosina A. (ORCID:0000-0002-0158-0583), Carbone L., Cuomo R., Vizzielli G., Siragusa, L., Angelico, R., Angrisani, M., Zampogna, B., Materazzo, M., Sorge, R., Giordano, Lucia, Meniconi, R., Coppola, A., Marino, A., Giraudo, G., Esposito, S., Urbani, A., De Pastena, M., Mastrapasqua, R., Garancini, M., Frontal, A., Pascal, G., Martellucc, J., Falb, F., Boscarelli, A., Bertoglio, P., Trecca, E., Galassi, L., Vento, V., Chiappini, A., Antonelli, A., Bennardo, F., Familiari, F., Giannaccare, G., Zappia, A. S., Giuliani, G., Falcone, F., Sebastiani, S., Montuori, M., Rossi, S., Sagnotta, A., Giuliani, B., Imbriani, G. C., Restaino, S., Andreani, L., Di Maria, F., Lagana, A. S., Vitiello, L., Berton, F., Virgilio, E., Palisi, M., Portigliotti, L., Calussi, M., Conti, L., Mauriello, C., Barone, Alessia Maria Addolorata, Saladino, E., Giaquinta, A., Zerb, D., Frazzetta, G., Merola, G., Chierici, A., Bini, R., Centonze, L., De Carlis, R., Ferrario, L., Giani, A., Lauterio, A., Tamini, N., Corti, Serafino, Botteri, E., Andreuccetti, J., D'Alessio, R., Cestaro, G., Clarizia, G., Spolini, A., Carboni, A. S., Benzoni, E., Galiffa, G., Perotti, B., Veroux, M., Randazzo, V., Topa, D., Pranteda, C., Contini, G., Iacusso, C., Voglino, V., Vita, P., Carrano, F. M., Ambrosio, L., Cammarata, R., Capolupo, G. T., Caputo, D., Carannante, F., Cascone, C., Esperto, F., Farolfi, T., Frasca, L., Gallo, I. F., Gibin, G., Giurazza, G., Improta, L., La Vaccara, V., Luffarelli, P., Luvero, D., Marangi, Giuseppe, Masciana, G., Mazzola, A., Mazzotta, E., Miligi, C. I., Montelione, N., Nenna, A., Orsaria, P., Papalia, R., Papalia, G. F., Parisi, F. R., Prata, F., Salzillo, R., Santini, Stefano Angelo, Sofo, F., Zampoli, A., Tanda, C., Altieri, G., Ardito, Francesco, Belia, Francesco, Bianchi, V., Biondi, Alberto, Brisinda, Giuseppe, Chiappetta, M., Ciolli, G., Ciolli, Alessandro, Ferracci, Federica, Ferri, L., Fico, V., Fiorillo, Claudio, Fransvea, Pietro, Galiandro, F., Giovinazzo, F., La Greca, Antonio, Litta, Francesco, Mele, C., Pafundi, D. P., Panettieri, Elena, Papa, Valerio, Patini, Romeo, Perrotta, Generoso, Puccioni, Caterina, Santocchi, P., Armatura, G., Olmi, S., Casoni Pattacini, G., Salgarello, S., Trompetto, M., Bombardini, C., La Rocca, R., Celentano, G., Micalef, A., Mazzella, A., Settembrini, A., Zoia, C., Degrate, L., Musumeci, Giampaolo, Palopoli, C. A. M., Montori, G., Bonati, E., Dinuzzi, V. P., Velluti, F., Balla, A., Bonasia, D. E., Coletta, D., Berardi, Giulia, Colasanti, M., Ferretti, Serena, Gasparoli, C., Mariano, Giuseppantonio, Avenia, S., Cianci, P., Cestino, L., Festa, F., Fazio, F., Ascari, F., Desio, M., Arroyo Murillo, G. A., Cereda, M., Galleano, R., David, G., Pansini, A., Gazia, C., Atzori, G., Desideri, L. F., Famularo, S., Galvanin, J., Giudici, V. M., Mangiameli, Gaetano, Mei, S., Milana, F., Pansa, A., Sacchi, Dario Marco, Testori, A., Di Carlo, Giampiero, Paratore, Mattia, Perrone, U., Vagge, A., Vigano, J., Torre, B., Scotti, M. A., Carbone, G., Cerchione, R., De Nardi, P., Gozzini, L., Ottaviani, Letizia, Senni, C., Piccin, O., Pio, L., Colombo, F., Avantifiori, R., Baldassarri, V., Caronna, R., Cicerchia, P. M., Corallino, D., Crocetti, D., Gallo, Giuseppe, Giovanardi, F., Giovannetti, F., Hassan, R., Iossa, A., Lai, Q., Lancellotti, F., Lucarini, A., Lucchese, S., Mazzarella, Giulio, Melandro, F., Minervini, A., Muttillo, E. M., Palmieri, L., Pasqua, R., Rosiello, F., Salina, Giulia, Sibio, S., Sirignano, P., Tarallo, M., Usai, S., Vanni, C., Viglietta, E., Zambon, M., Conversano, N. I., Epifani, A. G., Milano, Valentina, Sacco, L., Nava, Bruna Maria, Maffioli, A., Giuratrabocchetta, S., Baracchi, F., Zuolo, M., Ceresoli, M., Verdi, D., Belli, Andrea, Pata, F., Piovano, E., Pastore, G., Bernabei, F., Deiana, S., Arceri, A., D'Agostino, Cinzia, Marafante, C., Moggia, E., Parini, S., Moretti, M., Uggeri, F., Pontarolo, N., Fontana, T., Palmisano, Gerardo, Giuffrida, M., Guaitoli, E., Ferretti, C., Iacopino, G., Gioco, R., Roscitano, G., Montanelli, P., Chiappetta, M. F., Pinotti, E., Monati, E., Fazio, G., Di Pietro, F., Damarco, F., Barberis, A., Razzore, A., Pascale, A., Loi, S., Ferrara, F., Rossi, Marco, Lisi, G., Viel, G., Sasia, D., Bono, D., Cordaro, E. R., Giacomelli, E., Giani, I., Seriau, L., Pellino, Giuseppe, Sparavigna, M., Trigiante, G., D'Ambrogio, R. G., Cardella, F., Guzzetti, S., Luzzi, A. -P., Carganico, G., Drago, B., Micheletto, G., Orlandi, R., Cutolo, C., Gibello, U., Mistrangelo, M., Forcignano, E., D'Ugo, S., Losurdo, P., Manitto, M., Caroli, G., Franco, Manuela, Tilocca, P. L., Mendogni, P., Sena, G., Sambucci, D., Luciani, C., Atelli, P., Guida, Maria Antonietta, Marino, Filippo, Morini, A., Sibilla, M. G., Longo, Fabio, Giaccari, S., Vigorita, V., Balduzzi, A., Barra, F., Delogu, D., Milone, E., Bencini, L., Aprile, V., Papini, P., Montemurro, N., Cavallo, Michele, Picciariello, A., Tomasicchio, G., Fittipaldi, A., Maruccia, M., Gerardi, S., Cillara, N., Deidda, Silvia, Demarinis, G., Peiretti, E., Tatti, F., Iovino, C., Isola, G., Progno, V. C., Migliore, M., Badessi, G., Barilla, C., Calleri, G. S., Cianci, Stefano, Fama, F., Fleres, F., Mazzeo, C., Visaloco, M. G., Marchetto, C., Bolognesi, F., Benuzzi, L., Bracchetti, G., Brucchi, F., Manzo, C. A., Scaravilli, L., Ferrari, C., Rocca, A., Napolitano, Paola, Anoldo, P., Caricato, Chiara, Manigrasso, M., Milone, Maria, Napolitano, L., Palomba, G., Schiavone, V., Vetrella, M., Grossi, U., Moletta, L., Annicchiarico, A., Vella, I., Talesa, G., Boggi, U., Aiello, F., Anselmo, Anna, Bacchiocchi, G., Beati, F., Bellato, V., Billeci, F., Blasi, F., Buonomo, O. C., Campanelli, M., Coco, G., Contadini, A., Conte, L. E., D'Ippolito, G., Di Marcantonio, A., Spicchiale, C. F., Afflitto, G. G., Gismondi, A., Gorgolini, G., Granai, A. V., Grande, S., Gravina, A., Guida, A. M., Ingallinella, S., Keci, L., Latini, E., Marino, D., Oddi, F. M., Orecchia, L., Don, C. B. P., Pellicciaro, M., Petagna, L., Pirozzi, B. M., Quaranta, Caterina, Rho, M., Rosina, Alessandro, Santicchia, M. S., Saraceno, F., Schiavone, A., Sensi, B., Spina, A., Sullo, L., Tacconi, F., Taje, R., Vanni, G., Vinci, D., Vita, G., Alba, G., Badalucco, S., Carbone, Luigi, Samorani, O. C., Chisci, G., Cuomo, Rosa, Francia, A., Fusario, D., Gargiulo, B., Pasqui, E., Pasquetti, L., Puoti, P., Resca, L., Cumbo, J., Ganio, S., Vizzielli, Giuseppe, Anastasi, M., Guerra, D., Romanzi, A., Vannelli, A., Baia, M., Giordano L., Barone M., Corti S., Marangi G. (ORCID:0000-0002-6898-8882), Santini S. (ORCID:0000-0003-1956-5899), Ardito F. (ORCID:0000-0003-1596-2862), Belia F., Biondi A. (ORCID:0000-0002-2470-7858), Brisinda G. (ORCID:0000-0001-8820-9471), Ciolli A., Ferracci F., Fiorillo C. (ORCID:0000-0001-7681-3567), Fransvea P. (ORCID:0000-0003-4969-3373), La Greca A. (ORCID:0000-0002-7587-7427), Litta F., Panettieri E., Papa V. (ORCID:0000-0002-3709-8924), Patini R. (ORCID:0000-0001-7358-8763), Perrotta G., Puccioni C., Musumeci G., Berardi G., Ferretti S., Mariano G., Mangiameli G., Sacchi M. (ORCID:0000-0003-2826-8431), Di Carlo G., Paratore M., Ottaviani L. (ORCID:0009-0001-0967-8809), Gallo G., Mazzarella G., Salina G., Milano V., Nava M., Belli A., D'Agostino C., Palmisano G., Rossi M. (ORCID:0000-0002-4539-5670), Pellino G., Franco M., Guida A., Marino F., Longo F., Cavallo M., Deidda S., Cianci S., Napolitano P., Caricato C., Milone M., Anselmo A., Quaranta C., Rosina A. (ORCID:0000-0002-0158-0583), Carbone L., Cuomo R., and Vizzielli G.

Abstract

COVID-19 negatively affected surgical activity, but the potential benefits resulting from adopted measures remain unclear. The aim of this study was to evaluate the change in surgical activity and potential benefit from COVID-19 measures in perspective of Italian surgeons on behalf of SPIGC. A nationwide online survey on surgical practice before, during, and after COVID-19 pandemic was conducted in March–April 2022 (NCT:05323851). Effects of COVID-19 hospital-related measures on surgical patients’ management and personal professional development across surgical specialties were explored. Data on demographics, pre-operative/peri-operative/post-operative management, and professional development were collected. Outcomes were matched with the corresponding volume. Four hundred and seventy-three respondents were included in final analysis across 14 surgical specialties. Since SARS-CoV-2 pandemic, application of telematic consultations (4.1% vs. 21.6%; p < 0.0001) and diagnostic evaluations (16.4% vs. 42.2%; p < 0.0001) increased. Elective surgical activities significantly reduced and surgeons opted more frequently for conservative management with a possible indication for elective (26.3% vs. 35.7%; p < 0.0001) or urgent (20.4% vs. 38.5%; p < 0.0001) surgery. All new COVID-related measures are perceived to be maintained in the future. Surgeons’ personal education online increased from 12.6% (pre-COVID) to 86.6% (post-COVID; p < 0.0001). Online educational activities are considered a beneficial effect from COVID pandemic (56.4%). COVID-19 had a great impact on surgical specialties, with significant reduction of operation volume. However, some forced changes turned out to be benefits. Isolation measures pushed the use of telemedicine and telemetric devices for outpatient practice and favored communication for educational purposes and surgeon–patient/family communication. From the Italian surgeons’ perspective, COVID-related measures will continue to influence

Published
2023

7. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Author

Ferri, C., Raimondo, V., Giuggioli, D., Gragnani, L., Lorini, S., Dagna, L., Bosello, Silvia Laura, Foti, R., Riccieri, V., Guiducci, S., Cuomo, G., Tavoni, A., De Angelis, R., Cacciapaglia, F., Zanatta, E., Cozzi, F., Murdaca, G., Cavazzana, I., Romeo, N., Codullo, V., Pellegrini, R., Varcasia, G., De Santis, M., Selmi, C., Abignano, G., Caminiti, M., L'Andolina, M., Olivo, D., Lubrano, E., Spinella, A., Lumetti, F., De Luca, G., Ruscitti, P., Urraro, T., Visentini, M., Bellando-Randone, S., Visalli, E., Testa, D., Sciascia, G., Masini, F., Pellegrino, G., Saccon, F., Balestri, E., Elia, G., Ferrari, S. M., Tonutti, A., Dall'Ara, F., Pagano Mariano, G., Pettiti, G., Zanframundo, G., Brittelli, R., Aiello, V., Dal Bosco, Y., Di Cola, I., Scorpiniti, D., Fusaro, E., Ferrari, T., Gigliotti, P., Campochiaro, C., Francioso, F., Iandoli, C., Caira, V., Zignego, A. L., D'Angelo, S., Franceschini, F., Matucci-Cerinic, M., Giacomelli, R., Doria, A., Santini, Stefano Angelo, Fallahi, P., Iannone, F., Antonelli, A., Bosello S. L. (ORCID:0000-0002-4837-447X), Santini S. A. (ORCID:0000-0003-1956-5899), Ferri, C., Raimondo, V., Giuggioli, D., Gragnani, L., Lorini, S., Dagna, L., Bosello, Silvia Laura, Foti, R., Riccieri, V., Guiducci, S., Cuomo, G., Tavoni, A., De Angelis, R., Cacciapaglia, F., Zanatta, E., Cozzi, F., Murdaca, G., Cavazzana, I., Romeo, N., Codullo, V., Pellegrini, R., Varcasia, G., De Santis, M., Selmi, C., Abignano, G., Caminiti, M., L'Andolina, M., Olivo, D., Lubrano, E., Spinella, A., Lumetti, F., De Luca, G., Ruscitti, P., Urraro, T., Visentini, M., Bellando-Randone, S., Visalli, E., Testa, D., Sciascia, G., Masini, F., Pellegrino, G., Saccon, F., Balestri, E., Elia, G., Ferrari, S. M., Tonutti, A., Dall'Ara, F., Pagano Mariano, G., Pettiti, G., Zanframundo, G., Brittelli, R., Aiello, V., Dal Bosco, Y., Di Cola, I., Scorpiniti, D., Fusaro, E., Ferrari, T., Gigliotti, P., Campochiaro, C., Francioso, F., Iandoli, C., Caira, V., Zignego, A. L., D'Angelo, S., Franceschini, F., Matucci-Cerinic, M., Giacomelli, R., Doria, A., Santini, Stefano Angelo, Fallahi, P., Iannone, F., Antonelli, A., Bosello S. L. (ORCID:0000-0002-4837-447X), and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

Introduction: The impact of COVID-19 pandemic represents a serious challenge for ‘frail’ patients' populations with inflammatory autoimmune systemic diseases such as systemic sclerosis (SSc). We investigated the prevalence and severity of COVID-19, as well the effects of COVID-19 vaccination campaign in a large series of SSc patients followed for the entire period (first 38 months) of pandemic. Patients and method: This prospective survey study included 1755 unselected SSc patients (186 M, 1,569F; mean age 58.7 ± 13.4SD years, mean disease duration 8.8 ± 7.3SD years) recruited in part by telephone survey at 37 referral centers from February 2020 to April 2023. The following parameters were carefully evaluated: i. demographic, clinical, serological, and therapeutical features; ii. prevalence and severity of COVID-19; and iii. safety, immunogenicity, and efficacy of COVID-19 vaccines. Results: The prevalence of COVID-19 recorded during the whole pandemic was significantly higher compared to Italian general population (47.3 % vs 43.3 %, p < 0.000), as well the COVID-19-related mortality (1.91 % vs 0.72 %, p < 0.001). As regards the putative prognostic factors of worse outcome, COVID-19 positive patients with SSc-related interstitial lung involvement showed significantly higher percentage of COVID-19-related hospitalization compared to those without (5.85 % vs 1.73 %; p < 0.0001), as well as of mortality rate (2.01 % vs 0.4 %; p = 0.002). Over half of patients (56.3 %) received the first two plus one booster dose of vaccine; while a fourth dose was administered to 35.6 %, and only few of them (1.99 %) had five or more doses of vaccine. Of note, an impaired seroconversion was recorded in 25.6 % of individuals after the first 2 doses of vaccine, and in 8.4 % of patients also after the booster dose. Furthermore, the absence of T-cell immunoreactivity was observed in 3/7 patients tested by QuantiFERON® SARSCoV-2 Starter Set (Qiagen). The efficacy of vaccines, evalu

Published
2023

8. COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity

Author

Gragnani, L., Visentini, M., Lorini, S., Santini, Stefano Angelo, Lauletta, G., Mazzaro, C., Urraro, T., Quartuccio, L., Cacciapaglia, F., Ruscitti, P., Tavoni, A., Marri, S., Cusano, G., Petraccia, L., Naclerio, C., Treppo, E., del Frate, G., Di Cola, I., Raimondo, V., Scorpiniti, D., Monti, M., Puccetti, L., Elia, G., Fallahi, P., Basili, S., Scarpato, S., Iannone, F., Casato, M., Antonelli, A., Zignego, A. L., Ferri, C., Santini S. A. (ORCID:0000-0003-1956-5899), Gragnani, L., Visentini, M., Lorini, S., Santini, Stefano Angelo, Lauletta, G., Mazzaro, C., Urraro, T., Quartuccio, L., Cacciapaglia, F., Ruscitti, P., Tavoni, A., Marri, S., Cusano, G., Petraccia, L., Naclerio, C., Treppo, E., del Frate, G., Di Cola, I., Raimondo, V., Scorpiniti, D., Monti, M., Puccetti, L., Elia, G., Fallahi, P., Basili, S., Scarpato, S., Iannone, F., Casato, M., Antonelli, A., Zignego, A. L., Ferri, C., and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

Purpose: Mixed cryoglobulinemia syndrome (MCs) is a rare immunoproliferative systemic disorder with cutaneous and multiple organ involvement. Our multicenter survey study aimed to investigate the prevalence and outcome of COVID-19 and the safety and immunogenicity of COVID-19 vaccines in a large MCs series. Methods: The survey included 430 unselected MCs patients (130 M, 300 F; mean age 70 ± 10.96 years) consecutively collected at 11 Italian referral centers. Disease classification, clinico-serological assessment, COVID-19 tests, and vaccination immunogenicity were carried out according to current methodologies. Results: A significantly higher prevalence of COVID-19 was found in MCs patients compared to Italian general population (11.9% vs 8.0%, p < 0.005), and the use of immunomodulators was associated to a higher risk to get infected (p = 0.0166). Moreover, higher mortality rate was recorded in MCs with COVID-19 compared to those without (p < 0.01). Patients’ older age (≥ 60 years) correlated with worse COVID-19 outcomes. The 87% of patients underwent vaccination and 50% a booster dose. Of note, vaccine-related disease flares/worsening were significantly less frequent than those associated to COVID-19 (p = 0.0012). Impaired vaccination immunogenicity was observed in MCs patients compared to controls either after the first vaccination (p = 0.0039) and also after the booster dose (p = 0.05). Finally, some immunomodulators, namely, rituximab and glucocorticoids, hampered the vaccine-induced immunogenicity (p = 0.029). Conclusions: The present survey revealed an increased prevalence and morbidity of COVID-19 in MCs patients, as well an impaired immunogenicity even after booster vaccination with high rate of no response. Therefore, MCs can be included among frail populations at high risk of infection and severe COVID-19 manifestations, suggesting the need of a close monitoring and specific preventive/therapeutical measures during the ongoing pandemic.

Published
2023

9. Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study

Author

La Gualana, F., Maiorca, F., Marrapodi, R., Villani, F., Miglionico, M., Santini, Stefano Angelo, Pulcinelli, F., Gragnani, L., Piconese, S., Fiorilli, M., Basili, S., Casato, M., Stefanini, L., Visentini, M., Santini S. A. (ORCID:0000-0003-1956-5899), La Gualana, F., Maiorca, F., Marrapodi, R., Villani, F., Miglionico, M., Santini, Stefano Angelo, Pulcinelli, F., Gragnani, L., Piconese, S., Fiorilli, M., Basili, S., Casato, M., Stefanini, L., Visentini, M., and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

New-generation mRNA and adenovirus vectored vaccines against SARS-CoV-2 spike protein are endowed with immunogenic, inflammatory and immunomodulatory properties. Recently, BioNTech developed a noninflammatory tolerogenic mRNA vaccine (MOGm1 psi) that induces in mice robust expansion of antigen-specific regulatory T (Treg) cells. The Pfizer/BioNTech BNT162b2 mRNA vaccine against SARS-CoV-2 is identical to MOGm1 psi except for the lipid carrier, which differs for containing lipid nanoparticles rather than lipoplex. Here we report that vaccination with BNT162b2 led to an increase in the frequency and absolute count of CD4(pos)CD25(high)CD127(low) putative Treg cells; in sharp contrast, vaccination with the adenovirus-vectored ChAdOx1 nCoV-19 vaccine led to a significant decrease of CD4(pos)CD25(high) cells. This pilot study is very preliminary, suffers from important limitations and, frustratingly, very hardly can be refined in Italy because of the >90% vaccination coverage. Thus, the provocative perspective that BNT162b2 and MOGm1 psi may share the capacity to promote expansion of Treg cells deserves confirmatory studies in other settings.

Published
2023

12. Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases

Author

Ferri, Clodoveo, primary, Gragnani, Laura, additional, Raimondo, Vincenzo, additional, Visentini, Marcella, additional, Giuggioli, Dilia, additional, Lorini, Serena, additional, Foti, Rosario, additional, Cacciapaglia, Fabio, additional, Caminiti, Maurizio, additional, Olivo, Domenico, additional, Cuomo, Giovanna, additional, Pellegrini, Roberta, additional, Pigatto, Erika, additional, Urraro, Teresa, additional, Naclerio, Caterina, additional, Tavoni, Antonio, additional, Puccetti, Lorenzo, additional, Cavazzana, Ilaria, additional, Ruscitti, Piero, additional, Vadacca, Marta, additional, La Gualana, Francesca, additional, Cozzi, Franco, additional, Spinella, Amelia, additional, Visalli, Elisa, additional, Bosco, Ylenia Dal, additional, Amato, Giorgio, additional, Masini, Francesco, additional, Mariano, Giuseppa Pagano, additional, Brittelli, Raffaele, additional, Aiello, Vincenzo, additional, Scorpiniti, Daniela, additional, Rechichi, Giovanni, additional, Varcasia, Giuseppe, additional, Monti, Monica, additional, Elia, Giusy, additional, Franceschini, Franco, additional, Casato, Milvia, additional, Ursini, Francesco, additional, Giacomelli, Roberto, additional, Fallahi, Poupak, additional, Santini, Stefano Angelo, additional, Iannone, Florenzo, additional, Salvarani, Carlo, additional, Zignego, Anna Linda, additional, and Antonelli, Alessandro, additional

Published
2022
Full Text
View/download PDF

13. Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases

Author

Ferri, C., Gragnani, L., Raimondo, V., Visentini, M., Giuggioli, D., Lorini, S., Foti, R., Cacciapaglia, F., Caminiti, M., Olivo, D., Cuomo, G., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Cavazzana, I., Ruscitti, P., Vadacca, M., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Bosco, Y. D., Amato, G., Masini, F., Mariano, G. P., Brittelli, R., Aiello, V., Scorpiniti, D., Rechichi, G., Varcasia, G., Monti, M., Elia, G., Franceschini, F., Casato, M., Ursini, F., Giacomelli, R., Fallahi, P., Santini, Stefano Angelo, Iannone, F., Salvarani, C., Zignego, A. L., Antonelli, A., Santini S. A. (ORCID:0000-0003-1956-5899), Ferri, C., Gragnani, L., Raimondo, V., Visentini, M., Giuggioli, D., Lorini, S., Foti, R., Cacciapaglia, F., Caminiti, M., Olivo, D., Cuomo, G., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Cavazzana, I., Ruscitti, P., Vadacca, M., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Bosco, Y. D., Amato, G., Masini, F., Mariano, G. P., Brittelli, R., Aiello, V., Scorpiniti, D., Rechichi, G., Varcasia, G., Monti, M., Elia, G., Franceschini, F., Casato, M., Ursini, F., Giacomelli, R., Fallahi, P., Santini, Stefano Angelo, Iannone, F., Salvarani, C., Zignego, A. L., Antonelli, A., and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed at evaluating the seroconversion elicited by COVID-19 vaccine over the entire vaccination cycle including the booster dose. Among 478 unselected ASD patients originally evaluated at the end of the first vaccination cycle (time 1), 344 individuals were re-evaluated after a 6-month period (time 2), and 244 after the booster vaccine dose (time 3). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was assessed by measuring serum IgG-neutralizing antibody (NAb) on samples obtained at the three time points in both patients and 502 age-matched controls. In the 244 ASD group that received booster vaccine and monitored over the entire follow-up, the mean serum NAb levels (time 1, 2, and 3: 696.8 ± 52.68, 370.8 ± 41.92, and 1527 ± 74.16SD BAU/mL, respectively; p < 0.0001) were constantly lower compared to controls (p < 0.0001), but they significantly increased after the booster dose compared to the first two measurements (p < 0.0001). The percentage of patients with absent/suboptimal response to vaccine significantly decreased after the booster dose compared to the first and second evaluations (time 1, 2, and 3: from 28.2% to 46.3%, and to 7.8%, respectively; p < 0.0001). Of note, the percentage of patients with absent/suboptimal response after the booster dose was significantly higher compared to controls (19/244, 7.8% vs 1/502, 0.2%; p < 0.0001). Similarly, treatment with immune-modifiers increased the percentage of patients exhibiting absent/suboptimal response (16/122, 13.1% vs 3/122, 2.46%; p = 0.0031). Overall, the above findings indicate the usefulness of booster vaccine administration in ASD patients. Moreover, the persistence of a significantly higher percentage of individuals without effective seroconversion (7.8%), even after the booster dose, warrants for careful monitoring of NAb levels in a

Published
2022

14. Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2

Author

Visentini, M., Gragnani, L., Santini, Stefano Angelo, Urraro, T., Villa, A., Monti, M., Palladino, A., Petraccia, L., La Gualana, F., Lorini, S., Marri, S., Madia, F., Stefanini, L., Basili, S., Fiorilli, M., Ferri, C., Zignego, A. L., Casato, M., Santini S. A. (ORCID:0000-0003-1956-5899), Visentini, M., Gragnani, L., Santini, Stefano Angelo, Urraro, T., Villa, A., Monti, M., Palladino, A., Petraccia, L., La Gualana, F., Lorini, S., Marri, S., Madia, F., Stefanini, L., Basili, S., Fiorilli, M., Ferri, C., Zignego, A. L., Casato, M., and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

Studies on the safety and immunogenicity of SARS-CoV- 2 vaccination in patients with inflammatory rheumatic diseases have so far not included mixed cryoglobulinaemia (MC) vasculitis.1–3 We report a prospective observational multicentre study on this disorder.

Published
2022

15. SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance

Author

Franzese, M., Coppola, L., Silva, R., Santini, Stefano Angelo, Cinquanta, L., Ottomano, C., Salvatore, M., Incoronato, M., Santini S. A. (ORCID:0000-0003-1956-5899), Franzese, M., Coppola, L., Silva, R., Santini, Stefano Angelo, Cinquanta, L., Ottomano, C., Salvatore, M., Incoronato, M., and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

This study monitored the anti-spike-receptor-binding domain (RBD) and neutralizing antibodies induced by the Pfizer/BioNTech mRNA BNT162b2 vaccine in a cohort of 163 healthcare workers aged ≤60 years. We have taken advantage of two study groups, both of whom received the first two doses in the same time window, but Group 1 (54 HCWs) received the third dose 2 months before Group 2 (68 HCWs) did. The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7 months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose for Group 2; T9 = 1 month after the third dose for Group 2). The mean value of anti-spike antibodies decreased faster over time, but at T7, its decline was significantly slowed (T7 vs. T8*). After the third dose, the anti-spike titer rose about 34-fold (T7 vs. T8 and T8* vs. T9) and the booster improved the anti-spike titer by about three times compared with that of the second dose (T3 vs. T8 and T3 vs. T9), and no difference was noted between the two groups. The neutralizing titer was evaluated at T3, T7, T8, and T9. Anti-spike and neutralizing antibodies were found to be strongly correlated (r2 = 0.980; p < 0.001). At T3, 70% of the participants had a neutralizing antibody titer >91% of total anti-spike antibodies that increased to 90% after the third dose (T8 and T9). However, when the anti-spike titer reached its lowest value (T7), the neutralizing antibody levels decreased even further, representing only 44% of total anti-spike antibodies (p < 0.0001). Our findings show that the third vaccine dose improves the humoral response, but the wane of the a

Published
2022

16. COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies

Author

Gragnani, Laura, primary, Visentini, Marcella, additional, Lorini, Serena, additional, La Gualana, Francesca, additional, Santini, Stefano Angelo, additional, Cacciapaglia, Fabio, additional, Tavoni, Antonio, additional, Cuomo, Giovanna, additional, Fallahi, Poupak, additional, Iannone, Florenzo, additional, Antonelli, Alessandro, additional, Casato, Milvia, additional, Zignego, Anna Linda, additional, and Ferri, Clodoveo, additional

Published
2022
Full Text
View/download PDF

17. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups

Author

Ferri, Clodoveo, primary, Ursini, Francesco, additional, Gragnani, Laura, additional, Raimondo, Vincenzo, additional, Giuggioli, Dilia, additional, Foti, Rosario, additional, Caminiti, Maurizio, additional, Olivo, Domenico, additional, Cuomo, Giovanna, additional, Visentini, Marcella, additional, Cacciapaglia, Fabio, additional, Pellegrini, Roberta, additional, Pigatto, Erika, additional, Urraro, Teresa, additional, Naclerio, Caterina, additional, Tavoni, Antonio, additional, Puccetti, Lorenzo, additional, Varcasia, Giuseppe, additional, Cavazzana, Ilaria, additional, L'Andolina, Massimo, additional, Ruscitti, Piero, additional, Vadacca, Marta, additional, Gigliotti, Pietro, additional, La Gualana, Francesca, additional, Cozzi, Franco, additional, Spinella, Amelia, additional, Visalli, Elisa, additional, Dal Bosco, Ylenia, additional, Amato, Giorgio, additional, Masini, Francesco, additional, Pagano Mariano, Giuseppa, additional, Brittelli, Raffaele, additional, Aiello, Vincenzo, additional, Caminiti, Rodolfo, additional, Scorpiniti, Daniela, additional, Rechichi, Giovanni, additional, Ferrari, Tommaso, additional, Monti, Monica, additional, Elia, Giusy, additional, Franceschini, Franco, additional, Meliconi, Riccardo, additional, Casato, Milvia, additional, Iannone, Florenzo, additional, Giacomelli, Roberto, additional, Fallahi, Poupak, additional, Santini, Stefano Angelo, additional, Zignego, Anna Linda, additional, and Antonelli, Alessandro, additional

Published
2021
Full Text
View/download PDF

18. Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2

Author

Visentini, Marcella, primary, Gragnani, Laura, additional, Santini, Stefano Angelo, additional, Urraro, Teresa, additional, Villa, Annalisa, additional, Monti, Monica, additional, Palladino, Andrea, additional, Petraccia, Luisa, additional, La Gualana, Francesca, additional, Lorini, Serena, additional, Marri, Silvia, additional, Madia, Francesco, additional, Stefanini, Lucia, additional, Basili, Stefania, additional, Fiorilli, Massimo, additional, Ferri, Clodoveo, additional, Zignego, Anna Linda, additional, and Casato, Milvia, additional

Published
2021
Full Text
View/download PDF

20. SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged =60 years: One year of surveillance.

Author

Franzese, Monica, Coppola, Luigi, Silva, Romina, Santini, Stefano Angelo, Cinquanta, Luigi, Ottomano, Cosimo, Salvatore, Marco, and Incoronato, Mariarosaria

Subjects
MEDICAL personnel, ANTIBODY formation, COVID-19 vaccines, ANTIBODY titer, SARS-CoV-2
Abstract

This study monitored the anti-spike-receptor-binding domain (RBD) and neutralizing antibodies induced by the Pfizer/BioNTech mRNA BNT162b2 vaccine in a cohort of 163 healthcare workers aged =60 years. We have taken advantage of two study groups, both of whom received the first two doses in the same time window, but Group 1 (54 HCWs) received the third dose 2 months before Group 2 (68 HCWs) did. The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose forGroup 2; T9 = 1 month after the third dose for Group 2). The mean value of anti-spike antibodies decreased faster over time, but at T7, its declinewas significantly slowed (T7 vs. T8*). After the third dose, the anti-spike titer rose about 34-fold (T7 vs. T8 and T8* vs. T9) and the booster improved the anti-spike titer by about three times compared with that of the second dose (T3 vs. T8 and T3 vs. T9), and no difference was noted between the two groups. The neutralizing titer was evaluated at T3, T7, T8, and T9. Anti-spike and neutralizing antibodies were found to be strongly correlated (r2 = 0.980; p < 0.001). At T3, 70% of the participants had a neutralizing antibody titer >91% of total anti-spike antibodies that increased to 90% after the third dose (T8 and T9). However, when the anti-spike titer reached its lowest value (T7), the neutralizing antibody levels decreased even further, representing only 44% of total anti-spike antibodies (p < 0.0001). Our findings show that the third vaccine dose improves the humoral response, but the wane of the anti-spike and neutralizing antibody titers over time is more marked in the neutralizing antibodies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. SARS-CoV-2 was already circulating in Italy, in early December 2019

Author

Gragnani, L., Monti, M., Santini, Stefano Angelo, Marri, S., Madia, F., Lorini, S., Petraccia, L., Stasi, C., Basile, Umberto, Luti, V., Pagliai, F., Saccardi, R., Zignego, A. L., Santini S. A. (ORCID:0000-0003-1956-5899), Basile U., Gragnani, L., Monti, M., Santini, Stefano Angelo, Marri, S., Madia, F., Lorini, S., Petraccia, L., Stasi, C., Basile, Umberto, Luti, V., Pagliai, F., Saccardi, R., Zignego, A. L., Santini S. A. (ORCID:0000-0003-1956-5899), and Basile U.

Abstract

– OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified in China, in December 2019 determines COronaVIrus Disease 19 (COVID-19). Whether or not the virus was present in Italy earlier the first autochthonous COVID-19 case was diagnosed is still uncertain. We aimed to identify anti-SARS-CoV-2 antibodies in sera collected from 4th November 2019 to 9th March 2020, in order to assess the possible spread of the virus in Italy earlier than the first official national diagnosis. PATIENTS AND METHODS: Anti-SARS-CoV-2 antibodies were evaluated in retrospective serum samples from 234 patients with liver diseases (Hep-patients) and from 56 blood donors (BDs). We used two rapid serologic tests which were confirmed by a validated chemoluminescence assay. RESULTS: Via rapid tests, we found 10/234 (4.3%) IgG-positive and 1/234 (0.4%) IgM-positive cases in the Hep-patient group. Two/56 (3.6%) IgG-positive and 2/56 (3.6%) IgM-positive cases were detected in BD group. Chemoluminescence confirmed IgG-positivity in 3 Hep-patients and 1 BD and IgM-positivity in 1 Hep-patient. RNAemia was not detected in any of the subjects, rendering the risk of transfusion transmission negligible. CONCLUSIONS: Our results suggest an early circulation of SARS-CoV-2 in Italy, before the first COVID-19 cases were described in China. Rapid tests have multiple benefits; however, a confirmation assay is required to avoid false positive results.

Published
2021

22. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups

Author

Ferri, C., Ursini, F., Gragnani, L., Raimondo, V., Giuggioli, D., Foti, R., Caminiti, M., Olivo, D., Cuomo, G., Visentini, M., Cacciapaglia, F., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Varcasia, G., Cavazzana, I., L'Andolina, M., Ruscitti, P., Vadacca, M., Gigliotti, P., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Dal Bosco, Y., Amato, G., Masini, F., Pagano Mariano, G., Brittelli, R., Aiello, V., Caminiti, R., Scorpiniti, D., Rechichi, G., Ferrari, T., Monti, M., Elia, G., Franceschini, F., Meliconi, R., Casato, M., Iannone, F., Giacomelli, R., Fallahi, P., Santini, Stefano Angelo, Zignego, A. L., Antonelli, A., Santini S. A. (ORCID:0000-0003-1956-5899), Ferri, C., Ursini, F., Gragnani, L., Raimondo, V., Giuggioli, D., Foti, R., Caminiti, M., Olivo, D., Cuomo, G., Visentini, M., Cacciapaglia, F., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Varcasia, G., Cavazzana, I., L'Andolina, M., Ruscitti, P., Vadacca, M., Gigliotti, P., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Dal Bosco, Y., Amato, G., Masini, F., Pagano Mariano, G., Brittelli, R., Aiello, V., Caminiti, R., Scorpiniti, D., Rechichi, G., Ferrari, T., Monti, M., Elia, G., Franceschini, F., Meliconi, R., Casato, M., Iannone, F., Giacomelli, R., Fallahi, P., Santini, Stefano Angelo, Zignego, A. L., Antonelli, A., and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19. The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle. The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53–1203) vs 825 (451–1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients. Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subje

Published
2021

26. Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia

Author

Basile, Umberto, primary, Marino, Mariapaola, additional, Gragnani, Laura, additional, Napodano, Cecilia, additional, Gulli, Francesca, additional, Pocino, Krizia, additional, Lorini, Serena, additional, Santini, Stefano Angelo, additional, Basile, Valerio, additional, Miele, Luca, additional, Zignego, Anna Linda, additional, and Rapaccini, Gian Ludovico, additional

Published
2020
Full Text
View/download PDF

27. A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders

Author

Basile, Umberto, Francesca, Gulli, Maria Antonietta ISGRÒ, Napodano, Cecilia, Pocino, Krizia, Santini, Stefano Angelo, Laura, Gragnani, Laura, Conti, Rossi, Elena, Iole, Cordone, Anna Linda ZIGNEGO, Rapaccini, Gian Ludovico, Giovanni, Cigliana, Berruti, Federico, Laura, Todi, Marino, Mariapaola, and Di Stasio, Enrico

Subjects
Monoclonal Gammopathy, Biomarker, Biomarker, Free Light Chains, sCD138, Monoclonal Gammopathy, Free Light Chains, sCD138, Settore MED/05 - PATOLOGIA CLINICA
Published
2019

29. Evaluation of screening method for Bence Jones protein analysis

Author

Basile, Umberto, Gulli, Francesca, Torti, Eleonora, Napodano, Cecilia, Dell'Abate, Maria Teresa, De Santis, Elena, Santini, Stefano Angelo, Conti, Laura, Zuppi, Cecilia, Cigliana, Giovanni, Napodano, Cecilia (ORCID:0000-0002-8720-6284), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Zuppi, Cecilia (ORCID:0000-0003-4710-4934), Basile, Umberto, Gulli, Francesca, Torti, Eleonora, Napodano, Cecilia, Dell'Abate, Maria Teresa, De Santis, Elena, Santini, Stefano Angelo, Conti, Laura, Zuppi, Cecilia, Cigliana, Giovanni, Napodano, Cecilia (ORCID:0000-0002-8720-6284), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), and Zuppi, Cecilia (ORCID:0000-0003-4710-4934)

Abstract

No Abstract available

Published
2016

30. MON-448 Inflammatory and Oxidative Stress Parameters as Criteria of Classification of Metabolic Phenotypes of Insulin Resistance

Author

Bruno, Carmine, primary, Vergani, Edoardo, additional, Brunetti, Alessandro, additional, Ricerca, Bianca Maria, additional, Silvestrini, Andrea, additional, Meucci, Elisabetta, additional, Napodano, Cecilia, additional, Pocino, Krizia, additional, Gulli, Francesca, additional, Santini, Stefano Angelo, additional, Basile, Umberto, additional, and Mancini, Antonio, additional

Published
2019
Full Text
View/download PDF

31. Plasmatic free light chains in polycystic ovary syndrome

Author

Mancini, Antonio, primary, Brunetti, Alessandro, additional, Bruno, Carmine, additional, Vergani, Edoardo, additional, Pocino, Krizia, additional, Napodano, Cecilia, additional, Gulli, Francesca, additional, Santini, Stefano Angelo, additional, and Basile, Umberto, additional

Published
2019
Full Text
View/download PDF

34. IgG cryoglobulinemia

Author

Gulli, F, Basile, Umberto, Gragnani, L, Napodano, Cecilia, Pocino, Krizia, Miele, Luca, Santini, Stefano Angelo, Zignego, A L, Gasbarrini, Antonio, Rapaccini, G L, Basile, U, Napodano, C (ORCID:0000-0002-8720-6284), Pocino, K (ORCID:0000-0003-2456-5308), Miele, L (ORCID:0000-0003-3464-0068), Santini, S A (ORCID:0000-0003-1956-5899), Gasbarrini, A (ORCID:0000-0002-7278-4823), Gulli, F, Basile, Umberto, Gragnani, L, Napodano, Cecilia, Pocino, Krizia, Miele, Luca, Santini, Stefano Angelo, Zignego, A L, Gasbarrini, Antonio, Rapaccini, G L, Basile, U, Napodano, C (ORCID:0000-0002-8720-6284), Pocino, K (ORCID:0000-0003-2456-5308), Miele, L (ORCID:0000-0003-3464-0068), Santini, S A (ORCID:0000-0003-1956-5899), and Gasbarrini, A (ORCID:0000-0002-7278-4823)

Abstract

n/a

Published
2018

36. Vitamin D status in primary hyperparathyroidism: effect of genetic background

Author

Battista, C., Guarnieri, V., Carnevale, V., Baorda, F., Pileri, M., Garrubba, M., Salcuni, A. S., Chiodini, I., Minisola, S., Romagnoli, E., Eller-Vainicher, C., Santini, Stefano Angelo, Parisi, S., Frusciante, V., Fontana, A., Copetti, M., Hendy, G. N., Scillitani, A., Cole, D. E. C., Santini S. (ORCID:0000-0003-1956-5899), Battista, C., Guarnieri, V., Carnevale, V., Baorda, F., Pileri, M., Garrubba, M., Salcuni, A. S., Chiodini, I., Minisola, S., Romagnoli, E., Eller-Vainicher, C., Santini, Stefano Angelo, Parisi, S., Frusciante, V., Fontana, A., Copetti, M., Hendy, G. N., Scillitani, A., Cole, D. E. C., and Santini S. (ORCID:0000-0003-1956-5899)

Abstract

Primary hyperparathyroidism (PHPT) is associated with hypovitaminosis D as assessed by serum total 25-hydroxyvitamin D (TotalD) levels. The aim of this study is to evaluate whether this is also the case for the calculated bioavailable 25-hydroxyvitamin D (BioD) or free 25-hydroxyvitamin D (FreeD), and whether the vitamin D status is influenced by genetic background. We compared vitamin D status of 88 PHPT patients each with a matched healthy family member sharing genetic background, i.e., first-degree relative (FDR), or not, namely an in-law relative (ILR). We compared TotalD and vitamin D-binding protein (DBP), using the latter to calculate BioD and FreeD. We also genotyped two common DBP polymorphisms (rs7041 and rs4588) likely to affect the affinity for and levels of vitamin D metabolites. TotalD was lower (p < 0.001) in PHPT (12.3 ± 6.6 ng/mL) than either family member group (FDR: 19.4 ± 12.1 and ILR: 23.2 ± 14.1), whether adjusted for DBP or not. DBP levels were also significantly lower (p < 0.001) in PHPT (323 ± 73 mg/L) versus FDR (377 ± 98) or ILR (382 ± 101). The differences between PHPT and control groups for TotalD, BioD, and FreeD were maintained after adjustment for season, gender, and serum creatinine. 25-hydroxyvitamin D, evaluated as total, free, or bioavailable fractions, is decreased in PHPT. No difference was seen between first-degree relative and in-law controls, suggesting that neither genetic nor non-genetic background greatly influences the genesis of the hypovitaminosis D seen in PHPT.

Published
2017

37. The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals

Author

Maranghi, M, Prudente, S, D'Erasmo, L, Morini, E, Ciociola, E, Coletta, P, Verrienti, A, Arciello, S, Copetti, M, Pellegrini, F, Santini, Stefano Angelo, Morano, S, Filetti, S, Trischitta, V., Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Maranghi, M, Prudente, S, D'Erasmo, L, Morini, E, Ciociola, E, Coletta, P, Verrienti, A, Arciello, S, Copetti, M, Pellegrini, F, Santini, Stefano Angelo, Morano, S, Filetti, S, Trischitta, V., and Santini, Stefano Angelo (ORCID:0000-0003-1956-5899)

Abstract

Several studies have reported that the ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism (rs1044498) interacts with increased adiposity in affecting glucose homeostasis and insulin sensitivity. Conversely, one would expect that the amelioration of glucose homeostasis observed after weight loss is modulated by the ENPP1 K121Q polymorphism. The aim of our study was to test such hypothesis, in non-diabetic overweight-obese individuals.

Published
2013

38. Vitamin D and parameters of calcium homeostasis in inpatients with and without type 2 diabetes mellitus

Author

Carnevale, V, Inglese, M, Annese, Ma, De Matthaeis, A, Santini, Stefano Angelo, Frusciante, V, Fontana, A, Copetti, M, Pellegrini, F, D'Amico, G., Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Carnevale, V, Inglese, M, Annese, Ma, De Matthaeis, A, Santini, Stefano Angelo, Frusciante, V, Fontana, A, Copetti, M, Pellegrini, F, D'Amico, G., and Santini, Stefano Angelo (ORCID:0000-0003-1956-5899)

Abstract

Aim We investigated inpatients with and without type 2 diabetes mellitus, aged over 60 years, to compare their vitamin D status and calcium homeostatic parameters Materials and Methods We studied 140 patients consecutively admitted to our Internal Medicine Unit during the year 2010 (61 from November to April, 79 from May to October). The sample encompassed 70 patients with and 70 without diabetes. At admission we measured serum calcium (Ca), phosphate (P), sodium (Na), potassium (K), creatinine (Cr), alkaline phosphatase total activity (AP), albumin adjusted serum calcium (Caalb adj), 25 hydroxy-vitamin D (25OHD), parathyroid hormone (PTH), and 24-h urinary sodium/creatinine (uNa/Cr), potassium/creatinine (uK/Cr), calcium/creatinine (uCa/Cr), phosphate/creatinine (uP/Cr) ratios and calcium excretion (Ca ex). Results 25OHD levels of patients with and without diabetes did not significantly differ. In patients without diabetes recruited from November to April, 25OHD levels were significantly lower than those from May to October, whilst patients with diabetes did not show a significant seasonal variation. PTH had opposite non-significant seasonal variations, and negatively correlated with 25OHD in both groups of patients. This correlation was lost after adjusting for age and BMI in patients with diabetes. These inpatients had higher serum P and lower uP/Cr, according to lower PTH. Their serum glucose negatively correlated with uCa/Cr and Ca ex, contrary to inpatients with other diseases. Instead, uCa/Cr and Ca ex correlated with uNa/Cr only in patients without diabetes. Conclusions Inpatients with diabetes did differ from those with other disorders for vitamin D status and calcium-phosphate homeostatic mechanism.

Published
2012

39. Pharmacogenetics in older people: what we know and what we need to know

Author

Seripa, D, Paroni, G, Urbano, M, Santini, Stefano Angelo, D'Onofrio, G, Pilotto, A., Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Seripa, D, Paroni, G, Urbano, M, Santini, Stefano Angelo, D'Onofrio, G, Pilotto, A., and Santini, Stefano Angelo (ORCID:0000-0003-1956-5899)

Abstract

The prevalence of therapeutic failures (TFs) and adverse drug reactions (ADRs) markedly increased in older subjects. However, both TFs and ADRs did not always appear related to the presence of multiple pharmacologic treatments, a common status in subjects aged 65 and over. Instead, they seem more related to variations in the genes encoding protein metabolizing and transporting drugs. Thus, variations in these proteins may account for the inter-individual differences observed in drug efficacy, including the most severe clinical consequences TFs and ADRs. The genetics of drug metabolizing enzymes (DMEs) and drug transporters (DTs) is a very active area of multidisciplinary research, overlapping the fields of medicine, biology, pharmacology, and genetics. These proteins are virtually responsible for metabolism and disposition, and thus the efficacy, of a number of drugs currently used in clinical practice. This article explored some basic concepts of the pharmacogenetics of DMEs and DTs. We also focused current knowledge of the genetic basis of TFs and ADRs of the most common drugs currently used in geriatric clinics. The knowledge of what we know and what we need to know is needed to advance the application of pharmacogenetics in clinical practice, in order to introduce personalized treatments for elderly people.

Published
2012

40. Effectiveness of a High-Throughput Genetic Analysis in the Identification of Responders/Non-responders to CYP2D6-Metabolized Drugs

Author

Savino, Marinica, Seripa, D, Gallo, Ap, Garrubba, M, D'Onofrio, G, Bizzarro, Alessandra, Paroni, G, Paris, F, Mecocci, P, Santini, Stefano Angelo, Masullo, Carlo, Pilotto, A., Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Masullo, Carlo (ORCID:0000-0001-7798-3410), Savino, Marinica, Seripa, D, Gallo, Ap, Garrubba, M, D'Onofrio, G, Bizzarro, Alessandra, Paroni, G, Paris, F, Mecocci, P, Santini, Stefano Angelo, Masullo, Carlo, Pilotto, A., Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), and Masullo, Carlo (ORCID:0000-0001-7798-3410)

Abstract

Background: Recent studies investigating the single cytochrome P450 (CYP) 2D6 allele {*2A reported an association with the response to drug treatments. More genetic data can be obtained, however, by high-throughput based-technologies. Aim of this study is the high-throughput analysis of the CYP2D6 polymorphisms to evaluate its effectiveness in the identification of patient responders/non-responders to CYP2D6-metabolized drugs. Methods: An attempt to compare our results with those previously obtained with the standard analysis of CYP2D6 allele *2A was also made. Sixty blood samples from patients treated with CYP2D6-metabolized drugs previously genotyped for the allele CYP2D6*2A, were analyzed for the CVP2D6 polymorphisms with the AutoGenomics INFINITI (TM) CYP4502D6-I assay on the AutoGenomics INFINITI (TM) analyzer. Results: A higher frequency of mutated alleles in responder than in non-responder patients (75.38 \% vs 43.48 \%; p = 0.015) was observed. Thus, the presence of a mutated allele of CYP2D6 was associated with a response to CYP2D6-metabolized drugs (OR = 4.044 (1.348 - 12.154). No difference was observed in the distribution of allele *2A (p = 0.320). Conclusions: The high-throughput genetic analysis of the CYP2D6 polymorphisms better discriminate responders/non-responders with respect to the standard analysis of the CYP2D6 allele *2A. A high-throughput genetic assay of the CYP2D6 may be useful to identify patients with different clinical responses to CYP2D6-metabolized drugs. (Clin. Lab. 2011;57:887-893)}

Published
2011

41. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease

Author

Bizzarro, Alessandra, D'Onofrio, Guido, Paris, Fabio, Santini, Stefano Angelo, Masullo, Carlo, Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Masullo, Carlo (ORCID:0000-0001-7798-3410), Bizzarro, Alessandra, D'Onofrio, Guido, Paris, Fabio, Santini, Stefano Angelo, Masullo, Carlo, Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), and Masullo, Carlo (ORCID:0000-0001-7798-3410)

Abstract

Objective Cytochrome P450 (CYP) 2D6 enzyme is the major responsible for the metabolism of donepezil, an inhibitor of acetyl cholinesterase currently used for the symptomatic treatment of mild-to-moderate Alzheimer's disease (AD). Functional polymorphisms in the CYP2D6 gene may affect enzyme activity and thus, the metabolism of donepezil. The aim of this study was to evaluate the effect of 16 functional polymorphisms in the CYP2D6 gene on the clinical response to donepezil treatment in patients with mild-to-moderate AD. Methods In this multicenter prospective cohort study we evaluated 57 unrelated Caucasians clinically diagnosed as AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association Work Group criteria. Patients were treated with donepezil (5-10 mg/daily) for 6 months. The response to donepezil treatment was evaluated at 6-month follow-up according to the National Institute for Health and Clinical Excellence requirements. The identification of 16 clinically relevant CYP2D6 gene variants was performed by a high-throughput genetic analysis. Results Thirty-eight of 57 patients (67%) were responders and 19 patients (33%) were nonresponders to donepezil treatment. A significantly higher frequency of gene variants conferring decreased or absent enzyme activity was observed in responder than in nonresponder patients (73.68% vs. 36.84%; P = 0.005). The presence of gene variants conferring decreased or absent activity of the CYP2D6 enzyme was significantly associated with a clinical response to donepezil treatment (odds ratio = 6.286; 95% confidence interval = 1.828-21.667). Conclusions Functional polymorphisms in the CYP2D6 gene can influence the clinical efficacy of donepezil. The analysis of CYP2D6 genotypes may be useful in identifying subgroups of AD patients with different clinical response to donepezil treatment.

Published
2011

42. Increased cardiovascular risk among type 2 diabetic patients with high-normal albuminuria and no evidence of kidney impairment

Author

Cignarelli, M, Lamacchia, O, Gesualdo, L, Pilotti, A, Pacilli, Antonio, Santini, Stefano Angelo, De Cosmo, S., Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Cignarelli, M, Lamacchia, O, Gesualdo, L, Pilotti, A, Pacilli, Antonio, Santini, Stefano Angelo, De Cosmo, S., and Santini, Stefano Angelo (ORCID:0000-0003-1956-5899)

Abstract

Mounting evidence indicates that albuminuria in the ‘high-normal’ range is a predictor of cardiovascular morbidity and mortality . Which factors account for this increased risk and whether such a prediction is maintained even in the absence of a concomitant reduction of glomerular filtration rate (GFR) is unclear. To address this issue more in depth in the context of type 2 diabetes (T2D), we conducted a cross-sectional study of a cohort comprising 1148 (556 males/592 females) patients with T2D, age 60.4 ± 10 years, duration of diabetes 10.5 ± 9 years, with normoalbuminuria (male: albumin/creatinine ratio (ACR) = 0.72 (0.01–2.45); female: ACR = 0.88 (0.01–3.49) mg mmol −1 ) and no evidence of kidney impairment [e-GFR (MDRD) 89.5 ± 21 ml min −1 1.73 m −2 )]

Published
2011

43. Serological profile of asymptomatic HCV positive patients with low level of cryoglobulins.

Author

Basile, Umberto, Napodano, Cecilia, Pocino, Krizia, Gulli, Francesca, Santini, Stefano Angelo, Todi, Laura, Marino, Mariapaola, and Rapaccini, Gian Ludovico

Subjects
IMMUNOGLOBULIN G, RHEUMATOID factor, HEPATITIS C virus
Abstract

Clinical spectrum of hepatitis C virus (HCV)‐related cryoglobulinemia varies from an asymptomatic presentation to severe vasculitis and lymphoma. A recent study in HCV‐negative patients suggests that low cryoglobulins (CGs) levels are responsible for severe renal and neurological complications. The aim of this study was to identify a panel of serological biomarkers associated with low levels of CGs in HCV‐positive patients. We studied a population of 79 untreated patients with chronic HCV infection: 13 naïve patients without CGs; 28 patients with asymptomatic mixed cryoglobulinemia (MC) and low levels of CGs (16/28 with polyclonal type III and 12/28 with microheterogeneous type III CGs); 38 patients with symptomatic MC and high levels of type II CGs. Serum samples were collected and examined for rheumatoid factor (RF) IgG and IgM, free light chains (FLCs) and C3 and C4 complement components. We found that RF‐IgG and IgM, free k chains and k+λ were increased while C4 component was reduced, both in symptomatic and asymptomatic patients. Our results suggest that, even in absence of MC symptoms, the low levels of CGs may represent a trigger of activation for immune system in course of HCV infection. The identification of a correlated biomarkers panel could improve the clinical management of these patients and pave the way for target treatment strategies. © 2018 BioFactors, 45(3):318–325, 2019 [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. Oxidative stress, nitric oxide and diabetes.

Author

Pitocco, Dario, Zaccardi, Francesco, Di Stasio, Enrico, Romitelli, Federica, Santini, Stefano Angelo, Zuppi, Cecilia, Ghirlanda, Giovanni, Pitocco, Dario (ORCID:0000-0002-6220-686X), Di Stasio, Enrico (ORCID:0000-0003-1047-4261), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Zuppi, Cecilia (ORCID:0000-0003-4710-4934), Pitocco, Dario, Zaccardi, Francesco, Di Stasio, Enrico, Romitelli, Federica, Santini, Stefano Angelo, Zuppi, Cecilia, Ghirlanda, Giovanni, Pitocco, Dario (ORCID:0000-0002-6220-686X), Di Stasio, Enrico (ORCID:0000-0003-1047-4261), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), and Zuppi, Cecilia (ORCID:0000-0003-4710-4934)

Published
2010

45. Novel human pathological mutations. Gene symbol: UROD. Disease: porphyria, cutanea tarda

Author

Savino, M, Garrubba, M, Zelante, L, Aucella, F, Guida, Cc, Santini, Stefano Angelo, Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Savino, M, Garrubba, M, Zelante, L, Aucella, F, Guida, Cc, Santini, Stefano Angelo, and Santini, Stefano Angelo (ORCID:0000-0003-1956-5899)

Abstract

Novel human pathological mutations. Gene symbol: UROD. Disease: porphyria, cutanea tarda

Published
2010

46. Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients

Author

Santini, Stefano Angelo, Parrella, Paola, Barbano, Raffaella, Fazio, Vito Michele, Carella, Massimo, Savino, Maria, Murgo, Roberto, Valori, Vanna Maria, Garrubba, Maria, Copetti, Massimo, Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Santini, Stefano Angelo, Parrella, Paola, Barbano, Raffaella, Fazio, Vito Michele, Carella, Massimo, Savino, Maria, Murgo, Roberto, Valori, Vanna Maria, Garrubba, Maria, Copetti, Massimo, and Santini, Stefano Angelo (ORCID:0000-0003-1956-5899)

Published
2009

47. TYPE 2 DEIODINASE POLYMORPHISM (THR92ALA) PREDICTS L-THYROXINE DOSE TO ACHIEVE TARGET TSH LEVELS IN THYROIDECTOMIZED PATIENTS

Author

Torlontano, Massimo, Durante, Cosimo, Torrente, Isabella, Crocetti, Umberto, Augello, Giovanni, Ronga, Giuseppe, Montesano, Teresa, Travascio, Laura, Verrienti, Antonella, Bruno, Rocco, Santini, Stefano Angelo, D'Arcangelo, Palmina, Dallapiccola, Bruno, Filetti, Sebastiano, Trischitta, Vincenzo, Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Torlontano, Massimo, Durante, Cosimo, Torrente, Isabella, Crocetti, Umberto, Augello, Giovanni, Ronga, Giuseppe, Montesano, Teresa, Travascio, Laura, Verrienti, Antonella, Bruno, Rocco, Santini, Stefano Angelo, D'Arcangelo, Palmina, Dallapiccola, Bruno, Filetti, Sebastiano, Trischitta, Vincenzo, and Santini, Stefano Angelo (ORCID:0000-0003-1956-5899)

Published
2008

48. Increased levels of IGF-1 and beta2-microglobulin in epithelial lining fluid of preterm newborns developing chronic lung disease effects of rhG-CSF

Author

Capoluongo, Ettore Domenico, Vento, Giovanni, Ameglio, F., Lulli, Paola, Matassa, Piero Giuseppe, Carrozza, Cinzia, Santini, Stefano Angelo, Antenucci, Mirca, Castagnola, Massimo, Giardina, Bruno, Romagnoli, Costantino, Zuppi, Cecilia, Capoluongo, Ettore Domenico (ORCID:0000-0001-9872-0572), Vento, Giovanni (ORCID:0000-0002-8132-5127), Carrozza, Cinzia (ORCID:0000-0003-1045-0470), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Castagnola, Massimo (ORCID:0000-0002-0959-7259), Romagnoli, Costantino (ORCID:0000-0003-1176-2943), Zuppi, Cecilia (ORCID:0000-0003-4710-4934), Capoluongo, Ettore Domenico, Vento, Giovanni, Ameglio, F., Lulli, Paola, Matassa, Piero Giuseppe, Carrozza, Cinzia, Santini, Stefano Angelo, Antenucci, Mirca, Castagnola, Massimo, Giardina, Bruno, Romagnoli, Costantino, Zuppi, Cecilia, Capoluongo, Ettore Domenico (ORCID:0000-0001-9872-0572), Vento, Giovanni (ORCID:0000-0002-8132-5127), Carrozza, Cinzia (ORCID:0000-0003-1045-0470), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Castagnola, Massimo (ORCID:0000-0002-0959-7259), Romagnoli, Costantino (ORCID:0000-0003-1176-2943), and Zuppi, Cecilia (ORCID:0000-0003-4710-4934)

Abstract

Insulin-like growth factor-1 (IGF-1) is involved in regulating the Th-1/Th-2 balance, favoring the development of the Th-2 compartment which enhances fibrosis, one of the main characteristics of Chronic Lung Disease (CLD) in premature newborns. Limited data is available concerning a possible association between early epithelial lining fluid (ELF) concentrations of IGF-1 (total and free forms), IGF-binding protein-3 (IGFBP-3), beta2-microglobulin and subsequent development of CLD in preterm neonates. If neutropenic, preterm neonates are frequently treated with recombinant human granulocyte colony stimulating factor (rhG-CSF). The objective of the study was to correlate ELF concentrations of IGF-1 and beta2 microglobulin during the first week of life both in non-neutropenic and in rhGCSF-treated neutropenic preterm neonates, with subsequent development in CLD. Thirty preterm neonates with Respiratory Distress Syndrome (6 with neutropenia) were studied. Eleven out of 24 non-neutropenic preterm infants (46%) and all of the six neutropenic subjects (100%) developed CLD. With the exception of first day values, there was a clear similarity in the behaviors of assayed molecules between non-neutropenic and neutropenic patients developing CLD. Non-neutropenic patients without CLD showed significantly lower values of free IGF-1 and beta2M both on days 1 and 3. Total IGF-I and cell counts were different only on the 3rd day. Conclusions: 1) the mechanisms leading to CLD might be mediated by high levels of IGF-family molecules soon after birth 2) beta2M could be a marker of increased bronchoalveolar lavage fluid cellularity with potential inflammatory properties 3) G-CSF treatment induces an increased synthesis of IGF-1 molecules by cells recruited in the lung, with possible enhancement of the fibrogenic mechanisms.

Published
2006

49. Early prediction of postthyroidectomy hypocalcemia by one single iPTH measurement

Author

Lombardi, Celestino Pio, Raffaelli, Marco, Princi, Pietro, Santini, Stefano Angelo, Boscherini, Mauro, De Crea, Carmela, Traini, Emanuela, D'Amore, Annamaria, Carrozza, Cinzia, Zuppi, Cecilia, Bellantone, Rocco Domenico Alfonso, Lombardi, Celestino Pio (ORCID:0000-0001-8910-6693), Raffaelli, Marco (ORCID:0000-0002-1259-2491), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Boscherini, Mauro (ORCID:0000-0002-6359-5617), De Crea, Carmela (ORCID:0000-0002-7303-9657), Carrozza, Cinzia (ORCID:0000-0003-1045-0470), Zuppi, Cecilia (ORCID:0000-0003-4710-4934), Bellantone, Rocco Domenico Alfonso (ORCID:0000-0002-0844-3469), Lombardi, Celestino Pio, Raffaelli, Marco, Princi, Pietro, Santini, Stefano Angelo, Boscherini, Mauro, De Crea, Carmela, Traini, Emanuela, D'Amore, Annamaria, Carrozza, Cinzia, Zuppi, Cecilia, Bellantone, Rocco Domenico Alfonso, Lombardi, Celestino Pio (ORCID:0000-0001-8910-6693), Raffaelli, Marco (ORCID:0000-0002-1259-2491), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Boscherini, Mauro (ORCID:0000-0002-6359-5617), De Crea, Carmela (ORCID:0000-0002-7303-9657), Carrozza, Cinzia (ORCID:0000-0003-1045-0470), Zuppi, Cecilia (ORCID:0000-0003-4710-4934), and Bellantone, Rocco Domenico Alfonso (ORCID:0000-0002-0844-3469)

Abstract

BACKGROUND: We prospectively evaluated the possibility to make an early prediction of postthyroidectomy hypocalcemia by postoperative intact parathyroid hormone (iPTH) measurements. METHODS: Fifty-three consecutive patients who underwent bilateral thyroid resection were included; iPTH was measured preoperatively, at the end of the surgical procedure, and at 2, 4, 6, 24, and 48 hours after the operation. Patients who had hypocalcemia (serum total calcium, <8.0 mg/dL) were compared with normocalcemic patients. RESULTS: Sixteen patients experienced hypocalcemia. Six patients experienced symptoms. No significant difference was found between hypocalcemic and normocalcemic patients concerning demographic, pathologic, and preoperative laboratory data, surgical procedure, and intraoperative findings. Postoperative iPTH levels were reduced in hypocalcemic patients at the end of the procedure and at 2, 4, 6, 24, and 48 hours after the operation ( P < .001). IPTH levels below the normal range (<10 pg/mL) at 4 and 6 hours after the operation correctly predicted postoperative hypocalcemia and symptoms in all but 1 patient with a self-limiting, asymptomatic hypocalcemia (serum calcium concentration, 7.8 mg/dL) (specificity, 100%; sensitivity, 94%; overall accuracy, 98%). CONCLUSIONS: One single iPTH measurement reliably can predict, early after thyroidectomy, which patients are prone to clinically relevant postoperative hypocalcemia and necessitate supplementation treatment and which patients are eligible for a safe early discharge.

Published
2004

50. Chronic taaurine supplementation ameliorates oxidative stress and Na+ K+ ATPase impairment in the retina of diabetic rats

Author

Di Leo, Mauro, Santini, Stefano Angelo, Cicerone, S, Lepore, Domenico, Gentiloni Silveri, Nicolo', Caputo, Salvatore, Greco, Aldo Virgilio, Giardina, Bruno, Franconi, F, Ghirlanda, Giovanni, Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Lepore, Domenico (ORCID:0000-0002-2104-9239), Caputo, Salvatore (ORCID:0000-0003-0772-6800), Di Leo, Mauro, Santini, Stefano Angelo, Cicerone, S, Lepore, Domenico, Gentiloni Silveri, Nicolo', Caputo, Salvatore, Greco, Aldo Virgilio, Giardina, Bruno, Franconi, F, Ghirlanda, Giovanni, Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Lepore, Domenico (ORCID:0000-0002-2104-9239), and Caputo, Salvatore (ORCID:0000-0003-0772-6800)

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results